Mediverify Database
.png)
.png)
Welcome to the official website of the National Medicine Regulatory Authority of Sri Lanka. We are dedicated to ensuring the safety and efficacy of medicines for the people of Sri Lanka.
The National Medicine Regulatory Authority of Sri Lanka is committed to ensuring the safety, efficacy, and quality of medicines in the country. We strive to protect public health by regulating the manufacturing, importation, distribution, and sale of medicines.
NMRA regulates medicines, medical devices, borderline products imported to and manufactured in Sri Lanka. We also regulate pharmacies. Clinical trials conducted in Sri Lanka are also regulated by us.
Find Out MoreNational Medicines Quality Assuarance of the NMRA is responsible for the analyzing of the quality of any medicine, medical device or borderline product forwarded by the Authority. It functions as an additional approved analyst when the circumstance so requires.
Find Out MorePharmacovigilance Division is responsible for monitoring and dealing with adverse drug reaction, quality failure and counterfeit medicines.
Find Out MoreInspectorate and Enforcement Division is responsible for inspecting and investigating issues pertaining to proper implementation of the provision of the NMRA Act.
Find Out MoreNational Medicines Regulatory Authority,
State Engineering Corporation Building (2nd Floor),
No. 130,
W.A.D Ramanayaka Mawatha,
Colombo 02,
Sri Lanka
The National Medicines Regulatory Authority (NMRA) has granted a grace period until December 31, 2025, for all licensed retail pharmacies to renew their expired licenses.
This concession is crucial because, effective January 1, 2026, the NMRA will strictly enforce Clause 101 (2) of its regulations. This clause stipulates that a license will be
automatically cancelled if the renewal application is not submitted within three months of the current license's expiry date. Pharmacy owners are therefore advised to submit
renewals promptly to avoid cancellation.
Click Here for more : Notice to all retail and wholesale pharmacy owners
The National Medicines Regulatory Authority (NMRA) announces that the temporary suspension of accepting new retail pharmacy applications, which was in effect from 01 April 2025 to 01 October 2025, has been extended from 01 October 2025 until further notice.
This web notice is published to avoid inconvenience during customs importation, in accordance with the web notice issued on 5th March 2025. Relevant classification reports will be issued as early as possible.
[This publication has been initiated from 83rd (27/10/2025) and 84th (31/10/2025) Subcommittees of BPEC.]
Click Here : Rejected Borderline Product Classification Applications
Notice to All Authorized Local Agents,
This is to kindly inform all authorized local agents that the USD rate considered for the month of November 2025 for processing price details of medicines / medical devices is 306.11.
Please ensure that all price submission for MRP approvals are prepared accordingly.
